Also known as: ICS
FDA approved AstraZeneca's Breztri Aerosphere for asthma; EU CHMP recommended Trixeo. Phase 3 KALOS/LOGOS trials showed improved lung function and reduced severe exacerbations versus dual therapy.
FDA approves AstraZeneca's Breztri Aerosphere as the first single-inhaler triple therapy for asthma in patients aged 12+, based on Phase III KALOS and LOGOS trials showing improved lung function and reduced exacerbations versus dual therapy.
Phase III KALOS and LOGOS trial results published in The Lancet Respiratory Medicine show Breztri Aerosphere improved lung function and reduced severe asthma exacerbations compared to dual-combination therapies in patients with uncontrolled asthma.
